V
Virginia Bellido
Researcher at University of the Basque Country
Publications - 26
Citations - 217
Virginia Bellido is an academic researcher from University of the Basque Country. The author has contributed to research in topics: Medicine & Diabetes mellitus. The author has an hindex of 4, co-authored 10 publications receiving 82 citations.
Papers
More filters
Journal ArticleDOI
Impact of covid-19 lockdown on glycemic control in patients with type 1 diabetes.
TL;DR: It is suggested that having more time for self-management may help improve glycemic control in the short term, as well as the limitations of lockdown, which improved in patients with T1D.
Journal ArticleDOI
Inpatient Hyperglycemia Management and COVID-19.
Virginia Bellido,Antonio Pérez +1 more
TL;DR: This work intends to adapt established recommendations to manage hyperglycemia during this pandemic in critical and noncritical care settings to reduce barriers to better glycemic control.
Journal ArticleDOI
The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond.
Pratik Choudhary,Virginia Bellido,Matthijs Graner,Bernd Altpeter,Americo Cicchetti,Isabelle Durand-Zaleski,Finn Børlum Kristensen +6 more
TL;DR: In this article, the benefits of and challenges to wider application of telemedicine and telemonitoring in the post-pandemic future, with the aim to ensure that the value of these eHealth services is provided to patients, healthcare providers and health systems.
Journal ArticleDOI
Time-in-range for monitoring glucose control: Is it time for a change?
Virginia Bellido,Pedro José Pinés-Corrales,Rocío Villar-Taibo,Francisco Javier Ampudia-Blasco +3 more
TL;DR: Time in range (TIR) is a simple and intuitive metric that gives information regarding the quality of glucose control and is defined as the time spent in an individual's target glucose range as discussed by the authors.
Journal ArticleDOI
COVID-19 and Diabetes
Virginia Bellido,Antonio Pérez +1 more
TL;DR: In this paper, the effect of COVID-19 on DM patients in terms of glycemic control and the restrictions arising from the pandemic and assess management of diabetes and drug therapy in various scenarios.